AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2024, were $14.4 million, compared to $14.2 million for the same period in 2023. The increase was due ...

dedicated to the development and manufacturing of biologics following current good manufacturing practice (cGMP). Avid was ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a GMP certificate from the European Medicines Agency for its ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...

As a leading CDMO for bioconjugates, Lonza has produced over 1,000 cGMP batches for more than 70 programs since 2006. Lonza offers customers a fully integrated solution, spanning design and lead ...

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty ...

Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is up 47 ...

ADMA Biologics (NASDAQ:ADMA – Get Free Report) had its price objective raised by equities research analysts at HC Wainwright ...

SEOUL: Samsung Biologics on Tuesday said it has signed a deal worth $1.24 billion for contract manufacturing from an Asia-based biopharmaceutical firm. The deal will last until the end of 2037, the ...